Aviva PLC Increases Holdings in Boston Scientific Corporation $BSX

Aviva PLC grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 26.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,485,712 shares of the medical equipment provider’s stock after purchasing an additional 311,905 shares during the quarter. Aviva PLC’s holdings in Boston Scientific were worth $141,663,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in BSX. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth about $26,000. Murphy & Mullick Capital Management Corp increased its holdings in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the last quarter. Colonial Trust Co SC increased its holdings in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares during the last quarter. Bangor Savings Bank increased its holdings in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund purchased a new stake in Boston Scientific in the 4th quarter worth about $29,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

NYSE:BSX opened at $47.22 on Friday. The business has a 50 day moving average of $56.68 and a 200 day moving average of $75.14. The company has a market capitalization of $70.18 billion, a price-to-earnings ratio of 19.76, a PEG ratio of 0.91 and a beta of 0.56. Boston Scientific Corporation has a 1-year low of $46.91 and a 1-year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has initiated a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of analyst reports. BTIG Research decreased their price objective on Boston Scientific from $80.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, June 2nd. Leerink Partners cut their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research note on Thursday, May 28th. Oppenheimer set a $90.00 price target on Boston Scientific in a research report on Thursday, April 23rd. Stifel Nicolaus set a $75.00 price target on Boston Scientific in a research report on Wednesday, May 27th. Finally, Jefferies Financial Group decreased their price target on Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $85.92.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: BTIG reiterated a bullish view on Boston Scientific, highlighting a low forward P/E and significant upside potential, which may help support the stock after its sharp year-to-date de-rating. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Recent analyst commentary still shows broad Wall Street support, with several buy ratings and price targets well above the current trading range, suggesting some investors see the selloff as overdone.
• Neutral Sentiment: Boston Scientific’s Q1 results beat estimates slightly, with revenue up 11.6% year over year, but the market appears more focused on forward guidance and segment-level growth trends than the last quarter’s results.
• Neutral Sentiment: Erste Group trimmed FY2026 and FY2027 EPS estimates only modestly, signaling little change to the core earnings outlook, though the revisions add to the cautious tone around near-term expectations.
• Negative Sentiment: The stock has been sliding after a guidance reduction and renewed scrutiny over slower growth in important businesses, including WATCHMAN and ablation technologies, which is weighing on investor confidence. Boston Scientific Stock (BSX) Opinions on Recent Stock Decline
• Negative Sentiment: A recent market update showed BSX declined again in the latest session, reinforcing the bearish momentum that has followed the guidance-related selloff. Boston Scientific (BSX) Stock Moves -1.27%: What You Should Know

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.